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Abstract
Background: Human hepatic stellate cells have been shown to be resistant to apoptotic stimuli. This is likely dependent
on the activation of anti-apoptotic pathways upon transition of these cells to myofibroblast-like cells. In particular,
previous studies have demonstrated an increased expression of the anti-apoptotic protein Bcl-2 and a decreased
expression of the pro-apoptotic protein Bax during the transition of the hepatic stellate cell phenotype from quiescent
to myofibroblast-like cells. However, the role and expression of other key anti-apoptotic and survival pathways elicited
by polypeptide growth factors involved in the chronic wound healing process remain to be elucidated. In particular,
insulin growth factor-I promotes chemotactic and mitogenic effects in activated human hepatic stellate cells and these
effects are mediated by the activation of PI 3-K. The role of insulin growth factor-I as a survival factor in human hepatic
stellate cells needs to be substantiated. The aim of this study was to evaluate the involvement of other key anti-apoptotic
pathways such as PI-3K/Akt/p-Bad in response to insulin growth factor-I.
Results:  Insulin growth factor-I induced activation of Akt followed by Bad phosphorylation after 15 minutes of
incubation. These effects were PI-3k dependent since selective inhibitors of this molecule, wortmannin and LY294002,
inhibited both Akt and Bad phosphorylation. The effect of insulin growth factor-I on the activation of two downstream
targets of Akt activation, that is, GSK3 and FHKR, both implicated in the promotion of cell survival was also investigated.
Both targets became phosphorylated after 15 minutes of incubation, and these effects were also PI-3K-dependent.
Despite the activation of this survival pathway insulin growth factor-I did not have a remarkable biological effect, probably
because other insulin growth factor-I-independent survival pathways were already maximally activated in the process of
hepatic stellate cell activation. However, after incubation of the cells with a strong apoptotic stimuli such as Fas
ligand+cycloheximide, a small percentage of hepatic stellate cells underwent programmed cell death that was partially
rescued by insulin growth factor-I.
Conclusion: In addition to Bcl-2, several other anti-apoptotic pathways are responsible for human hepatic stellate cell
resistance to apoptosis. These features are relevant for the progression and limited reversibility of liver fibrosis in
humans.
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Background
Fibrosis and cirrhosis represent the consequences of a sus-
tained wound healing response to chronic liver disease
induced by a variety of causes, including viral, autoim-
mune, drug-related, cholestatic and metabolic damage.
The excessive accumulation of extracellular matrix occurs
in most types of chronic liver disease [1-5]. A key role in
fibrogenesis has been attributed to hepatic stellate cells
(HSCs), which have been identified as major collagen-
producing cells in an injured liver.
Following liver injury of any etiology, HSCs undergo a
response known as 'activation', which is the transition of
quiescent cells into proliferative, fibrogenic and contrac-
tile myofibroblasts (HSC/MFs) [1-5].
Numerous studies, performed in animal models of acute
or chronic liver injury, have shown a potential reversibil-
ity of liver fibrosis and cirrhosis [6]. Recovery from injury
in these animals is associated with apoptosis of the HSC/
MF and, as a consequence, a reduction in the tissue inhib-
itor of metalloproteinase (TIMP) levels and progressive
degradation of the fibrotic matrix [7-9].
In vitro studies, performed in rat HSCs, have investigated
the potential mechanisms regulating HSC apoptosis [10].
Rat HSCs have been shown to undergo apoptosis follow-
ing treatment with the pentapeptide GRGDS (Gly-Arg-
Gly-Asp-Ser), recombinant matrix metalloproteinase 9, an
antibody against focal adhesion kinase, Fas/fas ligand,
nerve growth factor (NGF), tumour necrosis factor α
(TNF-α), interferon gamma, selective peripheral benzodi-
azepine receptor ligands, and gliotoxin [11,12]. In addi-
tion, evidence has been provided concerning possible
candidate survival factors preventing HSC apoptosis,
including transforming growth factor 1, TIMP-1 and insu-
lin-like growth factor I (IGF-I) [1,10]. Overall, these stud-
ies have conveyed the message that HSC apoptosis
represents an important limiting step in the fibrogenic
process, particularly upon the discontinuation of chronic
tissue damage. In addition, these observations have high-
lighted the possible reversibility of fibrosis and even cir-
rhosis in humans [1,6].
However, these assumptions are based on animal models
where the extent and duration of tissue damage is limited
and short-lasting and on studies performed on rat HSCs.
Importantly, recent data by Novo et al. [13] suggest that
the dynamics of apoptosis in human HSCs could be
remarkably different from those observed in rat HSCs.
Activated human HSCs were shown to survive with pro-
longed serum deprivation, exposure to Fas ligand, NGF,
TNF-α, doxorubicin, ectoposide, oxidative stress media-
tors and 4-hydroxynonenal, thus indicating a strong
resistance of these cells to programmed cell death. In this
connection, these authors showed that the process of HSC
activation is accompanied by remarkable changes in the
expression of some key proteins involved in the control of
apoptosis, and in particular, a shift towards a higher Bcl2/
Bax ratio protein expression.
Based on this initial report, the aim of the present study
was to further characterise the pathways modulating the
apoptotic process in activated human HSCs. In order to
maximise this effort, the expression and regulation of dif-
ferent cytoplasmic and nuclear protein systems were eval-
uated before and following stimulation with IGF-I, a
factor known to support growth, metabolism, differentia-
tion and prevention of apoptosis in many cell types [14].
Although IGF-I is produced by many tissues, liver IGF-I
synthesis accounts for 90% of the circulating peptide. In
particular, liver IGF-I is synthesised at high levels in hepa-
tocytes in response to growth hormone stimulation [15],
and in multiple non-parenchymal cell types including
HSC [16]. These cells express IGF-I receptor and are
important targets for IGF-I action. In cultured HSCs, IGF-
I enhances proliferation [17], migration [18] and collagen
synthesis [19], providing indirect evidence that IGF-I
could play a role in the expansion of activated HSCs and
liver fibrosis.
In previous studies [18], we investigated the intracellular
pathway of human HSCs involved in both the mitogenic
and chemotactic effects. In particular, it was shown that
the activation of PI-3K and ERK is required for both IGF-
I-dependent HSC proliferation and chemotaxis, confirm-
ing an interaction between PI-3K/Akt and MAPK/ERK
pathways. The aim of this study was to investigate the
intracellular survival signal induced by IGF-I and its pos-
sible biological effect.
Materials and methods
Materials
Enhanced chemiluminescence (ECL) reagents and nitro-
cellulose membrane Hybond-C extra were from Amer-
sham Pharmacia Biotech. (Cologno Monzese, Milano,
Italy), IMMOBILON Western reagents were from the Mil-
lipore Corporation (Billerica, MA, US) IGF-I and platelet-
derived growth factor (PDGF) from Peprotech EC Ltd
(London, UK), Fas ligand (FasL) from Upstate Biotech.
(Lake Placid, New York, US). Antibody against Bad, Akt
(n-19) and poly (ADP-ribose) polymerase (PARP) were
from Santa Cruz Biotechnology (Santa Cruz, California,
US), all other antibodies were from Cell Signaling Tech-
nology (Danvers, MA, US). Iscove's medium was from
Invitrogen (Carlsbad, CA, US). Annexin-V-FLUOS stain-
ing kit was from Roche (Mannhein, Germany). All other
reagents were from Sigma Chemical Co. (Sigma Aldrich
Spa, Milano, Italy).Fibrogenesis & Tissue Repair 2009, 2:1 http://www.fibrogenesis.com/content/2/1/1
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Cell isolation and culture
The use of human material was approved by the Human
Research Review Committee of the University of Florence,
where cells were isolated and characterised from surgical
wedge sections of human livers not suitable for transplan-
tation, as described elsewhere [19]. Cells obtained from
samples of different normal human livers were cultured in
Iscove's medium supplemented with 20% foetal bovine
serum. After reaching confluence in the primary culture,
serial passages were obtained, always applying a 1:3 split
ratio. Cells were used between serial passages 4 and 7. At
this stage of culture, HSCs show phenotypic features of
fully activated HSC/MFs and a profile of cell surface mark-
ers identical to that of 'interface' MF described in fibrotic
and cirrhotic human livers [20,21]. HSC/MFs were plated
to obtain the desired subconfluence level (70–80%) and
then incubated for 24 hours in serum-free Iscove's
medium in order to obtain cells at the lowest level of
spontaneous proliferation before the addition of the dif-
ferent stimuli.
Western blot
Cells were lysed with 50 mM (4-(2-hydroxyethyl)-1-piper-
azineethanesulphonic acid (HEPES) buffer pH 7.5, 150
mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM
MgCl2, 1 mM ethylene glycol tetraacetic acid (EGTA), 10
μg/ml leupeptin, 10 μg/ml aprotinin, 1 mM phenylmeth-
ylsulphonyl fluoride and 100 mM sodium fluoride for 20
minutes at 4°C. Cells were scraped from dishes and cen-
trifuged at 15,000 g for 20 minutes at 4°C. Supernatants
were loaded for sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE) gel. After transferring the
proteins, blots were incubated with the desired primary
antibodies and then incubated with peroxidase conju-
gated anti-mouse or anti-rabbit immunoglobulins in Tris-
buffered saline-Tween containing 1% (weight/volume)
non-fat dry milk and developed with ECL reagents or
IMMOBILON Western reagents (chemiluminescent-HRP
substrate) according to the manufacturer's instructions.
Akt activity
An immune complex kinase assay of Akt activity was per-
formed as described elsewhere [22]. Briefly, 100 mg of
proteins were immunoprecipitated with anti-Akt antibod-
ies followed by adsorption to protein G-agarose. Immu-
noprecipitates were then collected by a brief
centrifugation and washed three times with washing
buffer (20 mM HEPES (pH 7.5), 40 mM NaCl, 50 mM
NaF, 1 mM ethylenediaminetetraacetic acid (EDTA), 1
mM EGTA, 0.5% Nonidet P-40, 20 mM b-glycerophos-
phate, 0.5 mM sodium orthovanadate, 1 mM phenyl-
methylsulphonyl fluoride, 10 mg/ml leupeptin, 10 mg/
ml pepstatin and 10 mg/ml aprotinin). The assay was per-
formed by resuspending the beads in kinase buffer (50
mM HEPES (pH 7.5), 100 mM NaCl, 10 mM MgCl2, 10
mM MnCl2, 10 mM b-glycerophosphate and 0.5 mM
sodium orthovanadate) in the presence of 1 mM protein
kinase A inhibitor peptide, 50 mM unlabelled ATP and 6
μCi of [γ-32P] ATP, using exogenous histone H2B (1.5
mg/assay tube) as the substrate and incubating for 20
minutes at room temperature. Reaction products were run
in a 12% SDS-PAGE, stained with Coomassie Blue and
visualised by autoradiography.
Evaluation of apoptosis
Evaluation of cell apoptosis was performed by evaluation
of PARP and caspase cleavage on Western blot.
Statistical analysis
All Western blots were representative of at least three to
four experiments with similar results. Statistical analysis
was performed by student's t-test. P values = 0.05 or 0.01
were considered significant.
Results
In the first set of experiments we investigated the IGF-I
intracellular signalling downstream of PI-3K activation.
As shown in Figure 1, IGF-I induced phosphorylation of c-
Akt on Ser 473 residue after 15 minutes of incubation.
This effect was PI-3K-dependent since it was blocked by
pre-incubation of HSCs with 100 nM WMN (Figure 1,
panel A) or 100 μM LY294002 (Figure 1, panel B), two
inhibitors of PI-3K. DES-(1–3) IGF-I, an analogue of IGF-
I able to interact with the IGF-I receptor without the inter-
ference of IGF binding proteins, was used as a positive
control for IGF-I action. PDGF was used as a positive con-
trol for the activation of PI-3K. To confirm that phospho-
rylation on Ser 473 induced Akt activity [23], an Akt
activation assay was then performed. Figure 2 illustrates
the activity of c-Akt measured by labelled phosphoryla-
tion of the exogenous histone 2B. Autoradiography
showed that IGF-I induced an increase in Akt activity
when compared with the control and this effect was
reversed by pre-incubation with LY294002 or WMN, thus
confirming a PI-3k activation dependency. Subsequently,
we verified the AKT-induced phosphorylation of Bad, a
pro-apoptotic protein, whose pro-apoptotic action is
blocked by phosphorylation and consequent association
with the 14-3-3t protein [24]. Cells were stimulated with
PDGF (Figure 3, panel A) and IGF-I (Figure 3, panel B).
Both growth factors were able to induce Bad phosphoryla-
tion after 15 minutes of incubation, an effect that resulted
at least in part to be PI3-K dependent. Since pre-incuba-
tion of cells with WMN or LY294002 could not com-
pletely reverse IGF-I-induced Bad phosphorylation, we
studied the involvement of ERK in this effect. Pre-incuba-
tion of HSCs with PD98059, an inhibitor of ERK activity,
did not affect PDGF and IGF-I-induced Bad phosphoryla-
tion, thus excluding an involvement of ERK/MAP kinase
as a regulatory mechanism (Figure 3, panel C). ProteinFibrogenesis & Tissue Repair 2009, 2:1 http://www.fibrogenesis.com/content/2/1/1
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expression of Bcl-xl and 14-3-3t was then evaluated after
24 hours of incubation with IGF-I and PDGF. As shown in
Figure 4, panel A, both growth factors increased Bcl-xl
expression, while 14-3-3t protein expression was not
modified (Figure 4, panel B). This observation suggests
that IGF-I is able to protect cells from apoptosis not only
after short-term stimulation but also for as long as 24
hours.
The effect of IGF-I on the activation of other proteins
downstream of the activation of Akt was also investigated.
The best-characterised Akt targets are the Forkhead box O
(FOXO) family of transcription factors and glycogen syn-
thase kinase 3β (GSK3β). FOXO proteins (FKHR, FKHR-
L1 and AFX) regulate different processes through tran-
scriptional effects on a large number of gene targets [25].
In resting conditions FOXO activates pro-apoptotic fac-
tors and cell-cycle-inhibitory proteins, while its Akt-
induced phoshorylation leads to a lack of activation of tar-
get proteins. GSK3β regulates different cellular processes
by phosphorylating many substrates including metabolic
enzymes, transcription factors, cell-cycle-regulatory pro-
teins and cytoskeletal proteins. This protein kinase is unu-
sual, as it is generally highly active in resting cells but
inhibited in response to cellular signals, in particular
through the PI-3K/Akt pathway [26-28]. As shown in Fig-
ure 5, phosphorylation of both GSK3β and FKHR was PI-
3K dependent after 15 minutes of incubation with IGF-I,
confirming an important role of this growth factor in cell-
cycle and apoptosis regulation.
Finally, the anti-apoptotic effects of IGF-I were further
evaluated on other effector mechanisms, that is, the cleav-
age of PARP and caspase 3 (two enzymes involved in the
final steps of apoptosis). As shown in Figure 6, exposure
of human HSCs to FasL+CHX induces cleavage of PARP
and this effect is partially reversed by co-incubation with
IGF-I. In addition, the cleavage of caspase 3 induced by
FasL+CHX was decreased by co-incubation with IGF-I
(Figure 7).
Discussion
The reversibility of fibrosis and even cirrhosis is currently
a central issue in hepatology. The introduction of more
effective anti-viral treatments and possibly anti-fibrogenic
agents is directed at reducing fibrosis as a key end-point
[29]. In this context, a clear definition of the cellular and
molecular mechanisms regulating apoptosis of fibrogenic
cell types, including HSCs, is urgently required. In addi-
tion, affinities and differences between experimental
models and human disease need to be better defined and
clarified. It is evident that in experimentally induced liver
fibrosis in rodents, cessation of liver injury results in fibro-
sis regression, usually associated with reduction of TIMP-
1 expression and HSC apoptosis. These observations are
Hepatic stellate cell extracts (20 μg proteins) were run on  10% sodium dodecyl sulphate polyacrylamide gel electro- phoresis gel and analysed by Western blot for pSer 473-Akt Figure 1
Hepatic stellate cell extracts (20 μg proteins) were 
run on 10% sodium dodecyl sulphate polyacrylamide 
gel electrophoresis gel and analysed by Western blot 
for pSer 473-Akt. Fifteen minutes of incubation with 100 
ng/ml of insulin-like growth factor I (IGF-I) induced phospho-
rylation of c-Akt in Ser 473 (lane 5 panel A and lane 4 panel 
B). This effect was PI-3K dependent since it was blocked by 
pre-incubation (30 minutes) of hepatic stellate cells with 100 
nM WMN (panel A) or 100 μM LY294002 (panel B), two 
established inhibitors of PI-3K. Platelet-derived growth factor 
was used as a positive control for p-Akt and DES-(1–3) IGF-I 
was used as a positive control for IGF-I. Barograms summa-
rise the results obtained in three independent experiments: * 
P < 0.05 or a higher degree of significance when compared 
with stimulation with growth factors without inhibitor.Fibrogenesis & Tissue Repair 2009, 2:1 http://www.fibrogenesis.com/content/2/1/1
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supported by in vitro studies performed in activated
rodent HSCs [7-10]. Based on this evidence, clearance of
activated HSCs by apoptosis has been regarded as an
appealing target for anti-fibrotic therapy [30]. However,
the regulation of apoptosis in activated human HSCs
deserves further evaluation. Novo et al. [13] have demon-
strated that activated human HSCs do not undergo spon-
taneous apoptosis and survive when exposed to
prolonged serum deprivation and numerous other pro-
apoptotic stimuli [31]. Induction of caspase-dependent,
mitochondria-driven apoptosis in human HSCs was
observed only when actinomycin D or cycloheximide
were added to the culture, indicating that de novo protein
expression contributes to resistance to apoptotic stimuli.
In particular, these authors observed an increasingly
higher expression of BCl-2 during the process of HSC acti-
vation. The possibility that human HSCs respond to pro-
apoptotic stimuli differently from rodent cells has raised
the need for a more extensive characterisation of the
responsible mechanisms and pathways involved in this
process. Accordingly, the aim of the present study was to
investigate the involvement of other key anti-apoptotic
pathways such as PI-3K/Akt/p-Bad in response to IGF-I.
The choice of IGF-I as a stimulus for these investigations
was based on extensive evidence of this polypeptide as a
potent survival factor. It has been shown in numerous cell
types that IGF-I acts through the activation of PI-3K and
several downstream molecules. In addition, other path-
ways are likely to be implicated in the cell survival action
of IGF-I, particularly ERK-kinase activation, Raf activation
and p38 activation [32].
The results of the present study confirmed that in acti-
vated human HSCs, IGF-I induced the activation of mole-
cules downstream of PI-3K. In particular, it was observed
that IGF-I can induce Akt activation and phosphorylation
of Ser 473 located in the C-terminal regulator domain of
the protein and this effect is totally dependent on PI-3K
activation since it was completed inhibited by wortman-
nin or LY294002. Phosphorylation at this site results in
the binding of Bad to 14-3-3t protein, thus inhibiting Bad
binding to Bcl-2 and Bcl-Xl. Of note, IGF-I-induced Bad
phosphorylation was not completely reversed by PI-3-K
inhibitors. This could be due to the fact that other IGF-I
activated proteins able to phosphorylate Bad are not acti-
vated by PI-3K. In this context we could exclude the
involvement of either ERK or PKA activation in Bad phos-
phorylation (data not shown).
In addition, exposure to IGF-I for 24 hours induced an
increased expression of the anti-apoptotic protein Bcl-Xl,
an anti-apoptotic protein that binds Bad. Taken together,
these data indicate that IGF-I could protect cells from
apoptosis acting both on anti-apoptotic signalling and the
expression of anti-apoptotic proteins.
We then evaluated the involvement of GSK3β in IGF-I-
induced PI-3K activation. GSK3β was initially identified
as an enzyme that regulates glycogen synthesis in
response to insulin. GSK3β is a ubiquitously expressed
serine/threonine protein kinase that phosphorylates and
inactivates glycogen synthase. GSK3β has been shown to
regulate cyclin D1 proteolysis and subcellular localisation
[33]. GSK3β knock-out mice show accelerated wound clo-
sure and fibrogenesis, thus suggesting an inhibitory role
Activity of Akt measured by labelled phosphorylation of the exogenous histone 2B Figure 2
Activity of Akt measured by labelled phosphorylation of the exogenous histone 2B. Autoradiography shows that 
insulin-like growth factor I (IGF-I) induced an increase in Akt activity (lane 4) when compared with the control and this effect 
was reversed by pre-incubation (30 minutes) with LY294002 (lane 5). DES-(1–3) IGF-I (lane 6) is an analogue of IGF-I that binds 
to the receptor but does not bind to the IGF-binding proteins.Fibrogenesis & Tissue Repair 2009, 2:1 http://www.fibrogenesis.com/content/2/1/1
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of this kinase [34]. In our experimental setting, IGF-I
induced the phosphorylation of GSK3β after 15 minutes
of incubation, and this effect was PI-3K-dependent. This
observation provides additional molecular insights into
the pro-survival action of IGF-I and reinforces its role in
the fibrogenic process.
Other downstream targets of Akt are the FOXO family of
transcription factors. Phosphorylation of FKHR family
Proteins (20 μg) obtained from cell extracts were run on a 12% sodium dodecyl sulphate polyacrylamide gel electrophoresis  and analysed by Western blot for Bad Figure 3
Proteins (20 μg) obtained from cell extracts were run on a 12% sodium dodecyl sulphate polyacrylamide gel 
electrophoresis and analysed by Western blot for Bad. Bad phosphorylation, shown by the protein shift, was evident 
for hepatic stellate cells treated with platelet-derived growth factor (PDGF) (panel A) and insulin-like growth factor I (IGF-I) 
(panel B). This effect was PI3-K dependent (lane 3), since it was inhibited by pre-incubation with WMN. Panel C shows the 
Western blot for Bad obtained with extracts from cells treated with PDGF (lane 2), IGF-I (lane 4) and DES (lane 6) for 15 min-
utes. It is evident that pre-incubation with PD98059 for 30 minutes did not have any effect on PDGF- and IGF-I-induced phos-
phorylation (lanes 3 and 5).Fibrogenesis & Tissue Repair 2009, 2:1 http://www.fibrogenesis.com/content/2/1/1
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members by Akt promotes cell survival and regulates the
cell cycle. Phosphorylation of FKHR protein regulates
their nuclear translocation and target gene transcription
[35]. Our data indicate that IGF-I induces the phosphor-
ylation of Fox 1 and Fox 4 of the Forkhead family and this
phosphorylation is strongly reduced by pre-incubation
with WMN, thus confirming a predominant anti-apop-
totic action of this growth factor through the activation of
PI-3K and related downstream pathways.
Finally, a dedicated set of experiments confirmed the
apoptosis-resistant phenotype of this activated human
HSC. Numerous factors were used to induce human HSC
apoptosis but only with high doses of FasL+cyclohex-
ymide, were caspase 3 and PARP cleavage observed. In
support of the survival action of IGF-I, incubation with
this growth factor resulted in a partial reversion of this
effect.
Conclusion
In conclusion, the results of the present study provided
additional insight into the regulation of apoptosis of
human HSCs, a key cell type involved in hepatic fibro-
genic disorders. Human HSCs in their MF-like phenotype
are characterised by the activation of several anti-apop-
totic pathways. This leads to a constitutive apoptotic-
resistant phenotype that is further supported by the pres-
ence of potent survival factors such as IGF-I. These features
likely contribute to the limited reversibility of long-term
liver fibrosis when the cause of damage is successfully
removed. Accordingly, the information provided by this
study will be instrumental in designing pharmacological
strategies able to promote HSC apoptosis.
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Delayed effects of insulin-like growth factor I on the expres- sion of proteins involved in the association of Bad Figure 4
Delayed effects of insulin-like growth factor I on the 
expression of proteins involved in the association of 
Bad. Insulin-like growth factor I (IGF-I), after 24 hours incu-
bation, induced an increase of expression of the pro-apop-
totic protein BCL-Xl (panel A, lane 4) but did not modify the 
expression of the 14-3-3t protein (panel B, lane 3) that asso-
ciates with Bad. Barograms summarise the results obtained in 
three independent experiments: * P < 0.05 or a higher 
degree of significance when compared with the control.Fibrogenesis & Tissue Repair 2009, 2:1 http://www.fibrogenesis.com/content/2/1/1
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Effect of insulin-like growth factor I on the phosphorylation of two targets, glycogen synthase kinase 3β (panel A) and FKHR  (panel B), downstream of Akt activation Figure 5
Effect of insulin-like growth factor I on the phosphorylation of two targets, glycogen synthase kinase 3β (panel 
A) and FKHR (panel B), downstream of Akt activation. Both GSK3β and FHKR were phosphorylated after 15 minutes 
of incubation with insulin-like growth factor I (lane 4) and the action was PI-3K dependent (lane 5). Barograms summarise the 
results obtained in three independent experiments (Panel C). * P < 0.05 or a higher degree of significance when compared with 
stimulation with growth factors without inhibitor.Fibrogenesis & Tissue Repair 2009, 2:1 http://www.fibrogenesis.com/content/2/1/1
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Western blot analysis for poly (ADP-ribose) polymerase expression Figure 6
Western blot analysis for poly (ADP-ribose) polymerase expression. The analysis was conducted with 20 μg of pro-
teins extracted from hepatic stellate cells treated with insulin-like growth factor I(IGF-I), FasL (20 ng/ml)+CHX (50 μg/ml) or 
IGF-I+FasL+CHX for 24 hours As shown, FasL+CHX could induce cleavage of poly (ADP-ribose) polymerase (lane 3) and this 
effect was partially inhibited by IGF-I (lane 4). The barogram summarises the results obtained in two independent experiments: 
* P < 0.05 when compared with incubation with FasL+CHX without IGF-I.Fibrogenesis & Tissue Repair 2009, 2:1 http://www.fibrogenesis.com/content/2/1/1
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